Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBITDA: 2016-2025

Historic EBITDA for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $62.1 million.

  • Collegium Pharmaceutical's EBITDA rose 78.21% to $62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.0 million, marking a year-over-year decrease of 18.86%. This contributed to the annual value of $169.9 million for FY2024, which is 1.76% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's EBITDA stood at $62.1 million, which was up 76.86% from $35.1 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year EBITDA high stood at $62.1 million for Q3 2025, and its period low was -$34.1 million during Q4 2021.
  • In the last 3 years, Collegium Pharmaceutical's EBITDA had a median value of $38.1 million in 2024 and averaged $41.4 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's EBITDA crashed by 327.54% in 2021, and later skyrocketed by 424.69% in 2023.
  • Collegium Pharmaceutical's EBITDA (Quarterly) stood at -$34.1 million in 2021, then surged by 134.46% to $11.8 million in 2022, then spiked by 424.69% to $61.7 million in 2023, then plummeted by 38.22% to $38.1 million in 2024, then skyrocketed by 78.21% to $62.1 million in 2025.
  • Its EBITDA stands at $62.1 million for Q3 2025, versus $35.1 million for Q2 2025 and $21.7 million for Q1 2025.